Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Assets Average (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Assets Average for 12 consecutive years, with $450.5 million as the latest value for Q4 2025.

  • Quarterly Assets Average rose 26.86% to $450.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $450.5 million through Dec 2025, up 26.86% year-over-year, with the annual reading at $419.9 million for FY2025, 14.07% up from the prior year.
  • Assets Average for Q4 2025 was $450.5 million at Theravance Biopharma, up from $420.7 million in the prior quarter.
  • The five-year high for Assets Average was $685.4 million in Q4 2022, with the low at $348.9 million in Q1 2025.
  • Average Assets Average over 5 years is $427.8 million, with a median of $400.0 million recorded in 2021.
  • The sharpest move saw Assets Average surged 76.22% in 2022, then crashed 41.97% in 2023.
  • Over 5 years, Assets Average stood at $389.0 million in 2021, then soared by 76.22% to $685.4 million in 2022, then tumbled by 41.97% to $397.8 million in 2023, then dropped by 10.72% to $355.1 million in 2024, then rose by 26.86% to $450.5 million in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $450.5 million, $420.7 million, and $384.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.